HIV Spotlight on Center on Caring for the Newly Diagnosed Patient

Recently Infected Individuals: A Priority for HIV Prevention

Fall 2011

 < Prev  |  1  |  2 

Challenge: Limitations of HIV Tests

The limitations of tests used to detect HIV infection is another major barrier to identifying recently infected individuals.

Several types of HIV tests are available but for each type of test there is a brief period of time after infection during which they are unable to detect infection in a person who is HIV-positive. The time period from when a person becomes infected with HIV to when an HIV test can detect their infection, is known as the "window period." During the "window period," an HIV test may find a recently infected person to be HIV-negative. The length of the "window period" is different for each type of test and varies from person to person.19

The HIV tests most commonly used in Canada look for antibodies to HIV in the blood. These tests cannot detect HIV infection in someone who has acute HIV infection because the body has not yet produced antibodies. The "window period" for antibody tests varies because some people produce antibodies faster than others. For most people (up to 95%), the window period of the antibody test is approximately one month, but for some individuals it may be as long as three months.


This means that for people at high risk of HIV, testing can be done as early as one month after exposure using standard antibody assays and rapid point-of-care tests. People who test positive will know for certain they are HIV-positive. Of those who test negative, 95% are indeed negative. Up to 5% of people who test negative at one month could later test positive at three months. It is important to ensure that people who test negative at one month are advised to return for repeat testing once the three-month window period is over.

Other HIV tests have been developed, which detect the virus itself -- such as the HIV RNA or the p24 antigen tests. These have shorter window periods (from seven to 14 days) than antibody tests and so can potentially detect HIV infection during the acute phase.20 Unfortunately, access to these new testing technologies varies across Canada.

Another limitation of HIV tests is the time it takes for many of them to produce results. Most HIV tests do not produce results immediately and require people to wait one to two weeks before getting the results. During this time, people may continue to engage in high-risk behaviours and some people may never return to get their test results.

Tests known as rapid or point-of-care (POC) tests can provide results on the same day that a test is performed. Most rapid/POC tests can provide results within minutes. This ensures that a person receives their results. Rapid tests that detect antibodies are available in some parts of Canada but rapid tests that can detect HIV RNA or the p24 antigen do not yet exist.


  • Frontline service organizations need to increase people's awareness of the different "window periods" for each type of HIV test, and emphasize that a negative result does not necessarily mean that a person is HIV-negative. Messaging should emphasize that a person who has recently tested HIV-negative may be in the "window period" and may be highly infectious. Knowledge of the "window period" and the increased risk of transmission during this time is particularly important for people who base their decisions of whether or not to have unprotected sex on knowledge of their HIV status or their partner's.
  • People who test HIV-negative within the "window period" should be encouraged to refrain from high-risk behaviours and return for another HIV test at an appropriate time. A second test is important to rule out the "window period" as the reason for the test being negative. In Canada, we encourage people who test HIV-negative on an antibody test to test again at the end of the three-month "window period," or sooner if appropriate.
  • Organizations should learn if, and where, rapid antibody testing or RNA/p24 testing is available in their area. A person who is suspected of being in the acute stage of HIV infection (for example, if they have recently had a high-risk exposure or they have experienced flu-like symptoms after the exposure) should be referred to a site where RNA or p24 testing is available. Service providers may need to advocate for improved access to rapid antibody testing and RNA/p24 tests in their area.


The goal of HIV prevention is to reduce the number of HIV infections in the communities we serve. A large number of HIV transmissions in your communities may be occurring from recently infected individuals, and therefore represent an important priority for HIV prevention efforts. Although several challenges exist in identifying these individuals and engaging them in prevention services, frontline organizations can play a key role in overcoming these challenges and reducing HIV transmissions.

Hottest at the Start -- A campaign by the Health initiative for Men (HiM) in BC to raise awareness on acute infection and transmission and to encourage gay men who have had a recent potential exposure to HIV to get an "early" HIV test.

James Wilton is the Project Coordinator of the Biomedical Science of HIV Prevention Project at CATIE. James has an undergraduate degree in Microbiology and Immunology from the University of British Columbia.


  1. Miller WC, Rosenberg NE, Rutstein SE, Powers KA. Role of acute and early HIV infection in the sexual transmission of HIV. Current Opinion in HIV and AIDS. 2010 Jul;5(4):277-82.
  2. Brenner BG, Roger M, Routy J et al. High rates of forward transmission events after acute/early HIV-1 infection. Journal of Infectious Diseases. 2007 Apr 1;195(7):951-9.
  3. Lindbäck S, Thorstensson R, Karlsson AC et al. Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. Karolinska Institute Primary HIV Infection Study Group. Swedish Institute for Infectious Disease Control/Karolinska Institute. AIDS. 2000 Oct 20;14(15):2333-9.
  4. Zetola NM, Pilcher CD. Diagnosis and management of acute HIV infection. Infectious Disease Clinics of North America. 2007 Mar;21(1):19-48.
  5. Morrison CS, Demers K, Kwok C et al. Plasma and cervical viral loads among Ugandan and Zimbabwean women during acute and early HIV-1 infection. AIDS. 2010 Feb 20;24(4):573-82.
  6. Pilcher CD, Eron JJ, Galvin S et al. Acute HIV revisited: new opportunities for treatment and prevention. Journal of Clinical Investigation. 2004 Apr;113(7):937-45.
  7. Schacker TW, Hughes JP, Shea T et al. Biological and virologic characteristics of primary HIV infection. Annals of Internal Medicine. 1998 Apr 15;128(8):613-20.
  8. Richardson BA, Mbori-Ngacha D, Lavreys L et al. Comparison of human immunodeficiency virus type 1 viral loads in Kenyan women, men, and infants during primary and early infection. Journal of Virology. 2003 Jun;77(12):7120-3.
  9. Pilcher CD, Joaki G, Hoffman IF et al. Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS. 2007 Aug 20;21(13):1723-30.
  10. Wawer MJ, Gray RH, Sewankambo NK et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. Journal of Infectious Diseases. 2005 May 1;191(9):1403-9.
  11. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. Journal of Infectious Diseases. 2008 Sept 1;198(5):687-93.
  12. Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. Journal of Acquired Immune Deficiency Syndromes. 2005 Aug 1;39(4):446-53.
  13. Moore ZS, McCoy S, Kuruc J et al. Number of named partners and number of partners newly diagnosed with HIV infection identified by persons with acute versus established HIV infection. Journal of Acquired Immune Deficiency Syndromes. 2009 Dec 1;52(4):509-13.
  14. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS. 2006 Jun 26;20(10):1447-50.
  15. Colfax GN, Buchbinder SP, Cornelisse PGA et al. Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion. AIDS. 2002 Jul 26;16(11):1529-35.
  16. Government of Canada Public Health Agency of Canada. HIV/AIDS Epi Updates -- July 2010 [cited 2011 May 12].
  17. Althoff KN, Gange SJ, Klein MB et al. Late presentation for human immunodeficiency virus care in the United States and Canada. Clinical Infectious Diseases. 2010 Jun 1;50(11):1512-20.
  18. Plitt SS, Mihalicz D, Singh AE et al. Time to testing and accessing care among a population of newly diagnosed patients with HIV with a high proportion of Canadian Aboriginals, 1998-2003. AIDS Patient Care and STDs. 2009 Feb;23(2):93-9.
  19. Cohen MS, Gay CL, Busch MP, Hecht FM. The detection of acute HIV infection. Journal of Infectious Diseases. 2010 Oct 15;202 Suppl 2:S270-7.
  20. Pilcher C, Christopoulos K, Golden M. Public health rationale for rapid nucleic acid or p24 antigen tests for HIV. Journal of Infectious Diseases. 2010 April 15;201 Suppl 1:S7-15.
 < Prev  |  1  |  2 

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.